Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. GNK
6. HTFL
7. SNDK
8. DVLT
9. ADYYF
10. WDAY

Go back to Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel

Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30

October 18, 2012 10:19 AM EDT

Needham & Company boosted its price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) from $22 to $30 after an FDA panel backed Lomitapide.

"Yesterday, an FDA Advisory Committee voted 13-2 in favor of approving lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). While... More

Aegerion (AEGR) Wins FDA Approval of Lomitapide in Lowering Cholesterol with HoFH Patients

October 17, 2012 3:52 PM EDT

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), said to win FDA approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with Homozygous Familial Hypercholesterolemia (HoFH).... More

Aegerion (AEGR) Trading Halted Ahead of Lomitapide FDA Committee Meeting

October 17, 2012 7:06 AM EDT

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced that NASDAQ has halted trading of the company's common stock today. The Endocrinologic and Metabolic Drugs... More